Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2015 - 2023)
Cartesian Therapeutics (RNAC) posted quarterly Non-Current Deffered Revenue of $3.5 million for Q4 2023, down 11.13% quarter-over-quarter from $4.0 million in Q3 2023.
Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2015 - 2023) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Non-Current Deffered Revenue for 9 consecutive years, with $3.5 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deffered Revenue changed N/A year-over-year to $3.5 million; the TTM figure through Dec 2023 stood at $3.5 million (changed N/A YoY), while the FY2023 annual figure was $3.5 million, changed N/A from the prior year.
- Non-Current Deffered Revenue retreated to $3.5 million in Q4 2023 per RNAC's latest filing, from $4.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $51.5 million in Q3 2020 and bottomed at $3.5 million in Q4 2023.
- Historically, Non-Current Deffered Revenue has averaged $16.3 million across 5 years, with a median of $14.7 million in 2020.
- Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue jumped 243.54% — and 2022, when it tumbled 72.9%.
- Cartesian Therapeutics' Non-Current Deffered Revenue stood at $14.7 million in 2019, then soared by 163.94% to $38.7 million in 2020, then sank by 70.53% to $11.4 million in 2021, then plunged by 52.39% to $5.4 million in 2022, then plunged by 34.92% to $3.5 million in 2023.
- Business Quant data shows RNAC's Non-Current Deffered Revenue at $3.5 million in Q4 2023, $4.0 million in Q3 2023, and $4.9 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 3.54 Mn |
| Sep 30, 2023 | 3.98 Mn |
| Jun 30, 2023 | 4.86 Mn |
| Mar 31, 2023 | 5.52 Mn |
| Sep 30, 2022 | 5.44 Mn |
| Jun 30, 2022 | 7.11 Mn |
| Mar 31, 2022 | 10.42 Mn |
| Dec 31, 2021 | 11.42 Mn |
| Sep 30, 2021 | 20.06 Mn |
| Jun 30, 2021 | 24.74 Mn |
| Mar 31, 2021 | 32.30 Mn |
| Dec 31, 2020 | 38.75 Mn |
| Sep 30, 2020 | 51.47 Mn |
| Jun 30, 2020 | 16.41 Mn |
| Mar 31, 2020 | 14.66 Mn |
| Dec 31, 2019 | 14.68 Mn |
| Sep 30, 2019 | 14.98 Mn |
| Jun 30, 2019 | 14.98 Mn |
| Mar 31, 2019 | 13.82 Mn |
| Dec 31, 2018 | 13.82 Mn |